Zevin Asset Management LLC lessened its holdings in Novartis AG (NYSE:NVS) by 22.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 47,065 shares of the company’s stock after selling 13,758 shares during the quarter. Novartis makes up approximately 1.5% of Zevin Asset Management LLC’s holdings, making the stock its 24th largest position. Zevin Asset Management LLC’s holdings in Novartis were worth $4,039,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Advisors Asset Management Inc. grew its holdings in shares of Novartis by 2.6% during the second quarter. Advisors Asset Management Inc. now owns 112,080 shares of the company’s stock worth $8,467,000 after purchasing an additional 2,803 shares during the last quarter. Bank of Montreal Can grew its holdings in shares of Novartis by 0.8% during the third quarter. Bank of Montreal Can now owns 168,393 shares of the company’s stock worth $14,509,000 after purchasing an additional 1,267 shares during the last quarter. Delaney Dennis R grew its holdings in shares of Novartis by 4.8% during the third quarter. Delaney Dennis R now owns 25,490 shares of the company’s stock worth $2,196,000 after purchasing an additional 1,170 shares during the last quarter. Somerville Kurt F grew its holdings in shares of Novartis by 1.8% during the third quarter. Somerville Kurt F now owns 178,301 shares of the company’s stock worth $15,363,000 after purchasing an additional 3,086 shares during the last quarter. Finally, Puzo Michael J grew its holdings in shares of Novartis by 1.8% during the third quarter. Puzo Michael J now owns 96,062 shares of the company’s stock worth $8,278,000 after purchasing an additional 1,721 shares during the last quarter. 10.99% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NVS traded down $0.38 during mid-day trading on Monday, hitting $88.47. 63,700 shares of the company’s stock were exchanged, compared to its average volume of 2,069,445. Novartis AG has a fifty-two week low of $72.30 and a fifty-two week high of $92.39. The company has a market capitalization of $205.24 billion, a price-to-earnings ratio of 17.36, a price-to-earnings-growth ratio of 1.93 and a beta of 0.69. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.97 and a current ratio of 1.20.

Novartis (NYSE:NVS) last announced its earnings results on Wednesday, January 30th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.33 by ($0.09). Novartis had a return on equity of 15.66% and a net margin of 24.30%. The business had revenue of $13.27 billion for the quarter, compared to analyst estimates of $13.33 billion. During the same quarter last year, the company posted $1.21 EPS. Novartis’s quarterly revenue was up 2.7% on a year-over-year basis. Equities research analysts forecast that Novartis AG will post 5.43 EPS for the current year.

The company also recently disclosed an annual dividend, which will be paid on Wednesday, March 13th. Investors of record on Tuesday, March 5th will be given a $2.8646 dividend. The ex-dividend date is Monday, March 4th. This represents a yield of 3.27%. This is an increase from Novartis’s previous annual dividend of $2.33. Novartis’s dividend payout ratio (DPR) is presently 37.52%.

Several brokerages have issued reports on NVS. JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of Novartis in a report on Tuesday, January 29th. Credit Suisse Group downgraded shares of Novartis to a “sell” rating in a research note on Thursday, December 20th. Zacks Investment Research upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $96.00 target price for the company in a research note on Tuesday, December 18th. Jefferies Financial Group reiterated a “buy” rating and set a $105.00 target price on shares of Novartis in a research note on Tuesday, December 11th. Finally, Barclays downgraded shares of Novartis from an “equal weight” rating to a “sell” rating in a research note on Friday, December 7th. Three analysts have rated the stock with a sell rating, six have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $90.94.

COPYRIGHT VIOLATION NOTICE: “Novartis AG (NVS) Position Reduced by Zevin Asset Management LLC” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2019/02/11/novartis-ag-nvs-position-reduced-by-zevin-asset-management-llc.html.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Further Reading: Trading Strategy Methods for Individual Investors

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.